ocrelizumab (ocrevus) Report issue

Biologics mAb Approved FDA Fast Track FDA Priority Review FDA

Active Ingredient History

NOW
  • Now
Ocrelizumab, sold under the brand name Ocrevus, is a pharmaceutical drug for the treatment of multiple sclerosis (MS). It is a humanized anti-CD20 monoclonal antibody. It targets CD20 marker on B lymphocytes and hence is an immunosuppressive drug. Ocrelizumab binds to an epitope that overlaps with the epitope to which rituximab binds.   Wikipedia

More Chemistry
  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

Australia

$6796.6675

United States

$12213.7400 - $16184.6700
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

2h7 | ocrelizumab | ocrevus | pr070769 | pr 070769 | pr-070769 | r1594 | r 1594 | r-1594 | rg-1594

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue